Loading
A phase 2 trial of sintilimab, cetuximab and dabrafenib in colorectal cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07506109 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 49 participants, started 2026-03-01 and due to reach its primary completion in 2027-12. Interventions recorded: Ipilimumab N01; Sintilimab; Cetuximab; Dabrafenib. Conditions listed: BRAF V600E; Colorectal Cancer; Sintilimab; MSS (Microsatellite Stable); Cetuximab; Dabrafenib; Ipilimumab N01. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: "Histologically or pathologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Sintilimab, Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Sintilimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Sintilimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/